Chikungunya

The Valneva single-shot chikungunya vaccine candidate induced protective neutralizing antibody titers in nearly 99% of study participants and was well tolerated, according to phase 3 trial results announced by the company.

Researchers found significant gaps in existing model-based predictions of Aedes mosquito distribution in the United States, reporting in a recent study that “the edges of the geographic range of these important species remain uncertain.”